-
Alkermes plc Reports First Quarter 2024 Financial Results
01 May 2024 14:29 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a global … IV" litigation and other patent litigation which may lead to …
-
Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript
16 Feb 2024 15:37 GMT
Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript February 15, 2024
Alkermes plc … morning. Welcome to the Alkermes plc conference call to discuss … relating to VIVITROL’s patent protection, which we … settlement of the VIVITROL patent matter, and most …
-
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
15 Feb 2024 12:38 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … the Janssen arbitration and VIVITROL patent litigation.
Balance Sheet
At Dec … IV" litigation and other patent litigation which may lead to …
-
Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript
26 Oct 2023 15:14 GMT
Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript October 25, 2023
Alkermes plc beats … successful settlement of the VIVITROL patent litigation, and the expected completion … with Teva to resolve our patent litigations related to VIVITROL. Under …
-
Alkermes plc Reports Third Quarter 2023 Financial Results
25 Oct 2023 14:39 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … successful settlement of the VIVITROL® patent litigation, and progress toward completion … , Inc. (Teva) to resolve the patent litigation between the parties related …
-
Alkermes plc Reports Second Quarter 2023 Financial Results
26 Jul 2023 14:05 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a fully … IV" litigation and other patent litigation which may lead to …
-
Alkermes plc Reports First Quarter 2023 Financial Results
26 Apr 2023 16:26 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a fully … IV" litigation and other patent litigation which may lead to …
-
JPM24: After 'clearing the decks,' Alkermes ready to roll as pure-play neuroscience company
10 Jan 2024 19:17 GMT
…
Those divestitures came after Alkermes won a lucrative arbitration …
Then in August, Alkermes settled a patent case with Teva, which … of patent protection.
While much of this was happening, Alkermes was … Alkermes is anxious to enter phase 2 study of ALKS 2680 …
-
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023
17 Feb 2023 06:57 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a fully … IV" litigation and other patent litigation which may lead to …
-
Alkermes Completes Separation of Oncology Business
15 Nov 2023 12:03 GMT
… PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it … legal counsel.
About Alkermes plc
Alkermes plc is a global … litigation and other patent litigation which may lead … this press release.
Alkermes plc and Subsidiaries
2023 Guidance …
About
© 1995-2024